ZLAB$18.845
Chart
Performance
Key Stats
AI ZLAB Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyZai Lab Limited shows strong long-term growth potential driven by its robust pipeline and expanding commercial portfolio in oncology and immunology. While recent performance has been strong, near-term valuation metrics and profitability require careful monitoring.
Thematic
Zai Lab is well-positioned in key therapeutic areas with significant unmet medical needs, benefiting from global biopharmaceutical trends and strategic partnerships.
Fundamental
The company demonstrates significant revenue growth and a strengthening balance sheet. However, persistent net losses and a negative EPS trend necessitate a focus on path to profitability.
Technical
The stock has shown strong recent performance, indicated by its significant 1-year return. However, some short-term technical indicators suggest potential overbought conditions or a need for consolidation.
| Factor | Score |
|---|---|
| Biopharmaceutical Innovation | 90 |
| Market Expansion & Partnerships | 88 |
| Oncology & Immunology Trends | 85 |
| Emerging Market Penetration | 82 |
| Regulatory Landscape | 70 |
| Factor | Score |
|---|---|
| Valuation | 45 |
| Profitability | 20 |
| Growth | 85 |
| Balance Sheet Health | 70 |
| Cash Flow | 30 |
| Factor | Score |
|---|---|
| Trend Analysis | 75 |
| Momentum | 55 |
| Performance | 90 |
| Moving Averages | 80 |
| Volume | 70 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Strong Recent Performance
The stock has shown robust performance over various periods, including 40.72% in the last 6 months and 100.27% in the last 1 year, indicating positive investor sentiment and potential for continued growth.
Attractive Price-to-Sales Ratio
The trailing Price-to-Sales (P/S) ratio is 13.2, and while this appears high, it's crucial to consider the company's growth stage and industry. For high-growth biopharmaceutical companies, a high P/S can be justified by strong future revenue potential.
Bearish Points (7)
Consistent Net Losses and Negative EPS
The company has consistently reported negative EPS and net income across all reported periods (TTM, 2021-2024), with significant losses. This indicates ongoing profitability challenges and reliance on funding for operations and growth.
High Price-to-Sales (P/S) Ratio
The trailing P/S ratio of 13.2 is notably high. While common in biotech, it implies high growth expectations are priced in, making the stock vulnerable to significant declines if growth targets are not met or if the market sentiment shifts.
Calendar
August 2025
7
Next Earnings Date
H: $-0.35
A: $-0.42
L: $-0.56
H: 132.31M
A: 125.02M
L: 113.80M
Profile
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company's oncology pipeline includes bemarituzumab, tumor treating fields, tisotumab vedotin, and repotrectinib; and immunology, neuroscience, and infectious disease pipeline comprises efgartigimod and xanomeline and trospium chloride. Zai Lab Limited has license and collaboration agreements with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure Ltd. to develop and commercialize Tumor Treating Fields; Deciphera Pharmaceuticals, LLC to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx BV to develop and commercialize efgartigimod; Bristol-Myers Squibb Company to develop and commercialize tisotumab vedotin and repotrectinib; Amgen Inc. to develop and commercialize bemarituzumab; Innoviva, Inc. to develop and commercialize Sulbactam-Durlobactam; and Karuna Therapeutics, Inc. to develop and commercialize Xanomeline and trospium chloride, as well as strategic collaboration with Pfizer Inc. for sulbactam and durlobactam. The company was incorporated in 2013 and is headquartered in Pudong, China.
Seasonals
Price Target
56.65 USD
The 39 analysts offering 1 year price forecasts for ZLAB have a max estimate of 75.00 and a min estimate of 41.40.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct competitor to Zai Lab, focused on oncology and autoimmune diseases with a strong presence in China and a similar global expansion strategy. Both companies actively pursue in-licensing and develop innovative therapies.
Weight: 90
Direct competitor and peer company, primarily focused on discovering, developing, and commercializing oncology and immunology drugs in China and globally. Similar R&D and commercialization model.
Weight: 88
Major Chinese biopharmaceutical company with a robust oncology pipeline and commercialization capabilities, operating within the same market and therapeutic areas as Zai Lab.
Weight: 85
Chinese biopharmaceutical company developing novel therapeutics and biosimilars, with a focus on oncology and autoimmune diseases, making it a relevant peer in the domestic market.